?' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity

Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, ?' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO(2)). The mean level of GPF in the patients with COVID-19 was significantly higher than in controls (69.8 (95 % CI 64.8-74.8) mg/dL compared with 36.9 (95 % CI 31.4-42.4) mg/dL, p < 0.0001), whereas C-reactive protein (CRP), lactate dehydrogenase (LDH), and total fibrinogen levels were not significantly different between groups. Mean GPF levels were significantly highest in patients with severe COVID-19 (SpO(2) = 93 %, GPF 75.2 (95 % CI 68.7-81.8) mg/dL), compared to mild/ moderate COVID-19 (SpO(2) > 93 %, GPF 62.5 (95 % CI 55.0-70.0) mg/dL, p = 0.01, AUC of 0.68, 95 % CI 0.57-0.78; Youden's index cutpoint 62.9 mg/dL, sensitivity 0.64, specificity 0.63). In contrast, CRP, interleukin-6, ferritin, LDH, D-dimers, and total fibrinogen had weaker associations with COVID-19 disease severity (all ROC curves with lower AUCs). Thus, GPF may be a useful inflammatory marker of COVID-19 respiratory disease severity.

Automated summary

COVID-19 is associated with a strong inflammatory response leading to organ failure, thrombosis, and death. A study investigated a novel inflammatory biomarker, GPF, in 103 hospitalized patients with COVID-19 and 19 healthy controls. The findings showed that GPF levels were significantly associated with the severity of COVID-19, and it may be a useful marker for evaluating the respiratory disease severity.